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Modulation of endoglin expression 
in islets of langerhans by VEGF reveals a novel 
regulator of islet endothelial cell function
Claire E. Clarkin1,2* , Marwa Mahmoud3, Bo Liu1, Emmanuel O. Sobamowo2, Aileen King1, Helen Arthur3, 
Peter M. Jones1† and Caroline P. Wheeler‑Jones4†
Background: Endoglin/CD105 is an auxiliary receptor for transforming growth factor‑β with established roles in vas‑
cular remodelling. It has recently been shown that heterozygous endoglin deficiency in mice decreases insulin secre‑
tion in an animal model of obesity, highlighting a potential role for endoglin in the regulation of islet function. We 
have previously identified two different populations of endoglin expressing cells in human and mouse islets which 
are: (i) endothelial cells (ECs) and (ii) islet mesenchymal stromal cells. The contribution of islet EC endoglin expression 
to islet development and sensitivity to VEGF is unknown and is the focus of this study.
Results: In vitro culture of mouse islets with VEGF164 for 48 h increased endoglin mRNA levels above untreated con‑
trols but VEGF did not modulate VEGFR2, CD31 or CD34 mRNA expression or islet viability. Removal of EC‑endoglin 
expression in vivo reduced islet EC area but had no apparent effect on islet size or architecture.
Conclusion: EC‑specific endoglin expression in islets is sensitive to VEGF and plays partial roles in driving islet vascu‑
lar development, however such regulation appears to be distinct to mechanisms required to modulate islet viability 
and size.
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Background
Native pancreatic islets are vascularised by a dense net-
work of microvessels that form an intra-islet portal sys-
tem which provides insulin secreting β-cells with highly 
oxygenated blood and offers a rapid route for trans-
port of insulin and islet hormones to reach their target 
tissues. The structural organisation of islets in which 
insulin-expressing β-cells are arranged in a specific pat-
tern around blood vessels [1, 2] highlight the potential 
importance of endothelial to endocrine cross talk in the 
regulation of islet function. During embryonic develop-
ment, reciprocal endothelial-endocrine signalling and the 
formation of functional blood vessels instruct pancreatic 
differentiation and morphogenesis [3–5].
Endoglin (Eng) is a homodimeric transmembrane 
glycol protein known to modulate cellular responses 
to ligands of the transforming growth factor (TGF)-β 
superfamily [6–9] and is expressed by vascular endothe-
lial cells (ECs) [10–12]. Eng expression levels in the vas-
culature increase during blood vessel sprouting and 
decreased Eng expression leads to altered angiogenesis 
in  vitro and aberrant vascular development and func-
tion in  vivo [13–16]. Eng deficient (Eng −/−) mice die 
at E10.5–11.5 from cardiovascular defects due to inap-
propriate remodeling of mature vascular network [14, 
16]. While Eng heterozygote (Eng±) mice are viable, they 
exhibit some of the vascular defects seen in humans with 
Eng haploinsufficiency [17]. A close relationship between 
Eng and pro-angiogenic vascular endothelial growth fac-
tor (VEGF) has been demonstrated in the differentiation 
of mouse embryonic stem cells (ESCs) in vitro, whereby 
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hematopoietic commitment within VEGF receptor 2 (R2) 
positive precursor populations are characterised by Eng 
expression [18].
Previous studies suggest an involvement of Eng in the 
alteration of islet function associated with the develop-
ment of diabetes. Thus, soluble plasma Eng levels have 
been reported to positively correlate with basal glycemia 
in patients with type 2 diabetes [19]. Mice with heterozy-
gous Eng deficiency exhibit increased glucose following 
insulin injection versus wild type controls and decreases 
in insulin levels following high fat diet, were also evident, 
highlighting some importance for Eng in the regulation 
of islet function. [20]. Our previous work has described 
the presence of two distinct populations of Eng posi-
tive cells residing within human and mouse islets of 
langerhans which are (i) islet endothelial cells (ECs) and 
(ii) islet mesenchymal stromal cells (MSCs) [21]. We 
have reported a unique anti-angiogenic function of Eng 
expressing MSCs in islets but the role of EC-specific Eng 
expression in the regulation of islet vascular development 
remains unreported, and is the focus of this study. Spe-
cifically, we have investigated whether Eng expression in 
islets can be regulated directly by a proangiogenic factor 
such as VEGF in  vitro. In addition, we have performed 
in  vivo studies in which Eng was deleted specifically in 
ECs to assess the effects on islet phenotype during early 
postnatal pancreatic growth.
Methods
Islets were isolated from male ICR mice (Harlan, Bices-
ter, UK) as previously described by our group [21]. Islets 
from 4 to 6 mice were combined and used for each indi-
vidual experiment which were repeated 3 times. For 
experiments using mitogens, media were refreshed every 
24 h. Mouse recombinant VEGF164 was purchased from 
R and D systems (Minneapolis, MN).
Transgenic mice expressing inducible Cre ERT2 recom-
binase under regulatory control of the mouse VE-cad-
herin gene promoter region [22] were crossed with the 
floxed endoglin line [23] to generate Engfl/fl; Cdh5(PAC) 
VE-Cadherin Cre-Ert2 mice (to be referred to as Eng-
iKOe) Cdh5(PAC)Cre-ERT2 mice were obtained from 
Dr Ralf Adams (CRUK, London). Eng fl/fl Cdh5(PAC)
Cre-ERT2 mice were backcrossed for 5 generations with 
C57BL/6 to generate an approximately syngeneic line. To 
activate Cre-ERT2, mice were injected subcutaneously 
with 0.5 mg tamoxifen at postnatal day (P)2 and P4 and 
pups sacrificed at P7. Genotyping was performed by PCR 
using genomic DNA template prepared from small tis-
sue biopsies. Pancreata from 4 control and 4 mutant mice 
were collected for analyses.
Immuno-staining of fixed pancreatic sections for insu-
lin, glucagon and CD34 has been described previously 
[11]. CD34-positive area was measured blind from light 
microscope images using Image J software. CD34 posi-
tive staining was quantified in 20 islets per mouse. For 
double labelling of Eng (Clone MJ7/18, provided as 
0.5 mg/ml stock solution, eBioscience) and CD31 (Clone 
MEC13.3, provided as 15.625  μg/ml stock solution, BD 
Biosciences, Pharmingen) pancreas cryosections were 
fixed and incubated with primary antibodies [endoglin 
(1:100) and CD31 (1:25)] followed by donkey anti-goat 
alexa 594 and goat anti-rat alexa 48.
Mouse islets were isolated from 4 to 6 mice and com-
bined for one experiment and each experiment was 
repeated 3 times. After isolation 150 islets counted, washed 
with PBS and lysed for RNA immediately. RNA was puri-
fied in preparation for RT-PCR according to manufactur-
er’s guidelines (Qiagen, Crawley, West Sussex, UK). Total 
cell RNA was reverse transcribed by incubating according 
to manufacturer’s instructions (Invitrogen, Paisley, UK) and 
standard PCR undertaken for amplification of mRNA from 
genes described in this manuscript (Primer sequences; 
[18]). Quantitative PCR each analysis using LC480 instru-
ment (Roche, Burgess Hill, UK) and SYBR green PCR 
reaction mix (Roche, as above) contained a range of stand-
ards (known concentrations of same target sequence) and 
analyzed using LC480 analysis software. The standard 
curve was plotted which correlated cycle number with the 
amount of product formed after each cycle. mRNA levels 
were normalized to β-actin for each sample.
Viability of whole islets, was assessed by measuring 
ATP using the CellTiter-Glo luminescent cell viability 
assay (Promega, Southampton, UK) [22]. After isolation 
20 islets where picked randomly and plated into a 96-well 
plate (6 wells/treatment). Each experiment was repeated 
3 times.
Results
Effects of exogenous VEGF164 on endoglin expression 
and islet viability
We have previously shown that Eng protein and mRNA 
expression in human and mouse islets is sustained during 
long-term culture of up to 2 weeks [21]. Consistent with 
this expression pattern we have now also found sustained 
expression of proangiogenic VEGF mRNA splice variants 
(120/164/188) in mouse islets cultured for up to 2 weeks 
(Fig. 1a). To establish whether exogenous VEGF164 could 
modulate Eng mRNA expression levels in islets, VEGF164 
(50  ng/ml) was added to freshly isolated mouse islet 
cultures for 48 h (media refreshed after 24 h) and RNA 
isolated. Quantitative PCR showed an increase in Eng 
mRNA following exposure to VEGF164 above cultured 
islet controls (Fig. 1b). This observation is in contrast to 
the mRNA levels of other endothelial cell markers includ-
ing VEGFR2, CD31 and CD34 which are all reduced after 
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3  days of culture and are unmodified by VEGF treat-
ment (Fig. 1c, d, e). To investigate how such changes in 
Eng mRNA may impact islet viability, freshly isolated 
mouse islets were treated with 50 ng/ml of VEGF164 for 
48 h and islet ATP levels were measured as an indicator 
of mitochondrial function and cell viability. VEGF had no 
apparent effect on islet ATP content (Fig. 1f ) demonstrat-
ing that the modulation of EC specific endoglin mRNA 
expression by VEGF is not linked to changes islet viability 
in vitro.
Fig. 1 VEGF164 increases endoglin expression in cultured islets but does not modify islet viability. RNA was isolated from 30 mouse islets either 
directly following isolation (fresh) or following 1 or 2 weeks of culture. PCR was then undertaken for mRNA levels of VEGF splice variants (a). Real 
time PCR was also undertaken for Endoglin (b) VEGFR2 (c) CD31 (d) and CD34 (e) with RNA isolated from either freshly isolated islets or follow‑
ing 48 h culture in the presence and absence of VEGF164 (50 ng/ml). Data are normalised to β‑actin and presented as % change with fresh islets 
normalised to 100 %. ATP levels in islets were measured following 48 h of VEGF164 (50 ng/ml) treatment (f). Data represent mean values + SEM and 
are from 3 separate mouse islet extractions
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Islet architecture in endothelial cell specific Eng knock 
out mice
To investigate the potential involvement of EC-specific 
Eng in modulating the islet phenotype in vivo we used an 
inducible EC-specific endoglin knock out mouse; Eng-
iKOe. Efficient Eng deletion in ECs following tamoxifen 
treatment of Eng-iKOe animals and litter mate wild type 
controls was first verified by double fluorescent labelling 
of Eng and CD31. CD31-positive cells within the islets of 
Eng-iKOe were devoid of Eng staining when compared 
to control wild type animals (Fig.  2a, b). In pancreases 
from Eng-iKOe, measurement of EC area per islet (as 
assessed by positive CD34 staining/islet area) was lower 
than that in islets from control mice (Fig. 2c, e), although 
CD34 staining was still detectable in mutant animals. 
In contrast, islet size and insulin and glucagon staining 
(for β/α-cell identification respectively) were not dif-
ferent in control versus mutant pancreases (Fig.  2d, f ). 
Classification of islets by size (i.e. <5000, 5000–10,000 
and >10,000 um2), also revealed no differences in the dis-
tribution of islet sizes between wild type and Eng-iKOe 
mice (Fig. 2g), confirming the lack of effect of EC-specific 
Eng deletion on islet morphology.
Discussion
Pancreatic islets are highly vascularised, which is impor-
tant not only during development but also in their abil-
ity to quickly secrete insulin in response to changes in 
blood glucose. In adults, VEGF is highly expressed and 
secreted by insulin-producing β-cells and is thought to 
contribute to the rich islet vascularisation [1–3]. Today, 
considerable effort is currently being devoted to establish 
Fig. 2 Loss of endothelial cell‑specific endoglin expression reduces total endothelial cell area per islet. Pancreases of endoglin fl/fl VE‑Cadherin 
Cdh5(PAC)Cre‑ERT2 (mutant) mice and endoglin fl/fl (control) P7 neonates were collected, processed and co‑labelled for CD31 and Endoglin to 
verify ablation of endoglin by ECs of mutant mice (a, b). Immunohistochemical analysis of CD34‑positive staining was undertaken using HRP‑DAB 
(eosin counterstain; c black arrows. Sections were also double labelled for insulin (fluorescein) and glucagon (texas red; d). Measurements of islet 
vascular density taken from ~20 islets/per mouse and expressed as CD34‑positive area (µm; e) per islet, total islet area (µm2; f), Islet size distribution 
was also analysed (%; g). Data are mean values (n = 4 animals per group) + SEM
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the effects of pro-angiogenic factors such as VEGF on the 
success of islet graft vascularization and survival of newly 
transplanted islets. In our study we found that addition 
of VEGF164 to freshly isolated islets for 48 h did not how-
ever influence islet viability, or the expression of endothe-
lial cell markers such as VEGFR2, CD31 and CD34.
The role of VEGF in improving islet transplantation 
outcomes is currently disputed; overexpression of VEGF 
in transplanted mouse islets caused increased vasculari-
sation and increased blood flow to newly transplanted 
islets, resulting in improved recipient glucose tolerance, 
and increased β-cell survival [1]. However in another 
study VEGFs removal from β-cells did not modify β-cell 
mass, but lead to insufficient islet vascularisation, result-
ing in defective insulin secretion [4].
VEGF is highly responsive to decreasing oxygen lev-
els and a hypoxia-responsive element downstream of 
the main transcription start site of the Eng gene has also 
been functionally characterised with hypoxic condi-
tions shown to up-regulate the Eng gene promoter, tran-
script and protein levels [24]. The high levels of VEGF, 
and Eng seen in our freshly isolated mouse islets, are 
predicted to be a consequence of the islet isolation pro-
cedure and following the loss contact with the systemic 
pancreatic blood supply. Given the high levels of these 
genes expressed by freshly isolated islets it was perhaps 
unsurprising that addition of exogenous VEGF served to 
further increase Eng mRNA levels by potentially exacer-
bating the hypoxic response. Whether direct modulation 
of Eng expression may provide a novel means to improve 
islet transplant outcomes via a positive influence on the 
vasculature is currently unclear, but regulation of its 
expression in islets may provide a novel route for possible 
interrogation.
To further investigate how modifications in EC spe-
cific-Eng expression may have implications for islet 
development in vivo, Eng was deleted from postnatal day 
2 until postnatal day 7 in all VE-Cadherin positive cells. 
We found that loss of EC specific Eng reduced EC num-
ber but did not impact islet growth and architecture at 
postnatal day 7. A recent study has shown that Eng is not 
required for the initial process of vasculogenesis, but is 
required for VEGF-induced angiogenesis, which could 
explain why deletion of Eng did not completely ablate 
all islet blood vessels [25]. To date, the role of EC-Eng 
expression during the tightly regulated steps of pan-
creatic development, and its control by VEGF, remains 
unclear but we have highlighted for the first time a direct 
involvement of Eng in islet vascular growth in  vivo. In 
addition, given our in  vitro observations whereby addi-
tion of VEGF can upregulate Eng mRNA, it is expected 
that expression of Eng in vivo will be tightly coordinated 
by the islets allowing for rapid and sufficient angiogenesis 
at times of growth and remodelling.
Our in  vivo studies demonstrated altered EC number 
following deletion of Eng expression which were inde-
pendent of changes in islet size and architecture at post-
natal day 7. An uncoupling of EC and β cell behaviour 
has been described with recent publications showing 
that changes in β-cell mass and insulin resistance were 
associated with modifications in vascular dilation of pre-
existing vessels but not through increased angiogenesis 
[26]. Furthermore, when VEGF was deleted postnatally in 
islets using β-cell specific DOX-inducible transgenics and 
a VEGF trap (Flt-1) EC regression and loss of EC fenestrae 
at 8–12  weeks of age was described. However, although 
islet hypovascularisation caused intraislet hypoxia in 
these animals, blood glucose was only marginally ele-
vated and did not affect insulin gene expression, pancreas 
insulin content or beta cell proliferation rate [27]. Addi-
tionally, in a study where VEGF was deleted in adult beta- 
cells although there was a 50 % reduction in the adult islet 
vasculature measured, islets were capable of maintaining 
their morphology, gene expression and beta cell mass, 
highlighting the remarkable ability islets have to survive 
and function when intraislet endothelial cells are reduced 
[28]. Similarly, our observations that the reduction in EC 
number following Eng deletion did not influence the size 
or architecture of individual islets, nor the overall beta cell 
mass as assessed by islet area, is further evidence for an 
uncoupling of endothelial/beta cell behaviour. As the vas-
culature is still detectable in islets when Eng is removed 
in combination with the published role for Eng in regu-
lating angiogenesis not vasculogenesis [25] it is possible 
that there remains sufficient vascularisation necessary for 
normal islet growth within this particular stage of devel-
opment. Since previous studies suggest that the functional 
beta cell mass is the primary predictor of metabolic con-
trol [27–29] the Eng deletion is alone unlikely to exert a 
metabolic phenotype, although this should be confirmed 
in future studies.
Conclusions
We have shown that in isolated islets VEGF can directly 
increase Eng mRNA expression levels and that Eng is 
required in part for islet EC growth during development. 
Therefore, modulation of Eng expression may provide 
a novel route to improve islet graft revascularisation. 
Our findings showing no effect of EC specific-Eng dele-
tion on islet phenotype may point towards independent 
mechanisms driving islet vascularisation and islet growth 
in early development. Future investigations interrogat-
ing the relationship between islet ECs and beta-cells are 
required to better understand the pathways involved in 
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promoting and maintaining islet vascular function which 
could be manipulated in clinical settings.
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